Ensuring safe and effective drugs: who can do what it takes?
- 11 January 2011
- Vol. 342 (jan11 1), c7258
- https://doi.org/10.1136/bmj.c7258
Abstract
Drawing on their experience in producing a Cochrane review of neuraminidase inhibitors for influenza, Tom Jefferson and colleagues discuss how to improve the reliability of systematic reviewsThis publication has 16 references indexed in Scilit:
- Rosiglitazone: what went wrong?BMJ, 2010
- Reporting bias in medical research - a narrative reviewTrials, 2010
- We want raw data, nowBMJ, 2009
- Point-by-point response from Roche to BMJ questionsBMJ, 2009
- Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysisBMJ, 2009
- Searching for unpublished trials in Cochrane reviews may not be worth the effortJournal of Clinical Epidemiology, 2009
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesThe New England Journal of Medicine, 2007
- Neuraminidase inhibitors for preventing and treating influenza in healthy adultsPublished by Wiley ,2006
- Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and HospitalizationsArchives of Internal Medicine, 2003
- Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute InfluenzaJAMA, 2000